AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

J. Giffin, Michael; S. Cooke, Keegan; K. Lobenhofer, Edward; Estrada, Juan; Zhan, Jinghui; Deegen, Petra; Thomas, Melissa; M. Murawsky, Christopher; Werner, Jonathan; Liu, Siyuan; Lee, Fei; Homann, Oliver; Friedrich, Matthias; T. Pearson, Joshua; Raum, Tobias; Yang, Yajing; Caenepeel, Sean; Stevens, Jennitte; J. Beltran, Pedro; Canon, Jude; Coxon, Angela; M. Bailis, Julie; E. Hughes, Paul

doi:10.1158/1078-0432.ccr-20-2845

Public

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Shared by NobleBlocks on Nov 17, 2020 • 12:00 AM UTC

Authors:

Michael J. Giffin

Keegan S. Cooke

Edward K. Lobenhofer

Abstract

PURPOSE: Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high relapse rate, limited therapeutic options, and poor prognosis. We investigated the antitumor activity of AMG 757, a half-life extended bispecific T-cell engager molecule targeting delta-like ligand 3 (DLL3)-a ta...

Subject

Cancer research

Medicine

Cell

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!